Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study
Our data suggested that for OS, the combination therapy has sustained benefits for both patients with stage B and C, But for PFS, the benefits of the combination therapy among the stage C patients, could not be persistently demonstrated by the current datasets.
Authors
- Qiaomei Zheng
- Jingyi Dai (ORCID: https://orcid.org/0000-0002-9210-8902)
- Virasakdi Chongsuvivatwong (ORCID: https://orcid.org/0000-0002-9850-4463)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-0045-311X)
- Yu Luo (ORCID: https://orcid.org/0000-0003-4620-3869)
- Gui‐Xin Zhao (ORCID: https://orcid.org/0000-0002-4363-8253)
- Yadi Ding (ORCID: https://orcid.org/0009-0001-8350-9659)
- Lingqing Zou
Institutions
- Hubei University of Medicine (CN)
- Prince of Songkla University (TH)
- Kunming Third People's Hospital (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/cmar.s511364
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64